Last updated: February 22, 2025

Endometriosis is the presence of endometrial glands and stroma outside the normal location, excluding adenomyosis. It is a hormonally dependent disease, and therefore commonly presents as cyclical pelvic pain. Prevents chiefly in women of reproductive age. Should be considered as a differential in a pt presenting with ongoing pelvic pain and infertility/subfertility. Sx may overlap with adenomyosis. Tx depends on specific sx, severity, location, and desire for future fertility.

Prevalence of 2-10%. More common in East Asians > whites > blacks.

  • Risk factors
    • Familial clustering (Increased incidence in first-degree relatives)
    • Genetic mutations/polymorphisms (some gene mutation candidates have been considered as risk factors – PTEN, EMX2)
    • Anatomic defects (increased incidence w/ outflow tract obstruction)
    • Nulliparity
    • Early menarche
    • Late menopause
    • Short menstrual cycle (< 27 days)
    • Menorrhagia (> 1 week)
    • Other environmental factors
      • TCDD/Dioxins (industrial pollutants)
      • Caffeine
      • Alcohol use
  • Protective factors
    • Regular exercise
    • High parity
    • Longer duration of lactation
  • Theories behind the cause of endometriosis
    • Retrograde menstruation: dissemination of endometrial fragments into the peritoneal cavity d/t uterine hyperperistalsis/dysperistalsis. Explains endometriosis in women with outflow obstruction.
    • Lymphatic/vascular spread: theory behind spread into weird tissues e.g. implants behind the eye
    • Coelomic metaplasia (Meyer’s theroy): suggests that the parietal peritoneum is pluripotent and can transform into endometrial tissue. Explains why some men can get endometriosis (chronic pelvic pain with Hx of hyperestrogenism)
    • Induction theory: exposure to estrogen induces tranformation of certain tissues into endometrial-like tissue. Ovarian surface epithelium can transform into endometrial like-tissue.
    • Immune dysfunction: very complex…
  • Pathophysiology
    • Regardless of location of endometrial tissue it responds to the normal hormonal cycle resulting in:
      • Production of inflammatory and pain mediators
      • Infertility
      • Nerve dysfunction
    • There is increased prostaglandin and oestrogen formation leading to chronic inflammation (IL 1, IL6, IL 8, TNF alpha all play a role) = PAIN
    • Premenstruation – the tissue is stimulated to grow by progesterone and oestrogen. They enlarge and undergo secretory changes and bleeding.
    • However, surrounding tissues prevent expansion and enlargement of the hemorrhagic fluid causing an increase in pressure = PAIN
    • Severe pain is seen in cases where there are deeply infiltrating lesions.
  • Signs and symptoms
    • Chronic Pelvic pain (severity correlated with depth of invasion)
      • Localized
      • Radiating to the upper back or leg
    • Pain Sx (chronic or cyclical, or cyclical superimposed on chronic)
      • Dysmenorrhoea (pain precedes menses by 24-48H, Less responsive to NSAIDs and COCs)
      • Dyspareunia (partly caused by implants in the uterosacral ligament)
      • Dysuria (associated with cyclical frequency and urgency)
      • Defecatory pain
    • Infertility/subfertility (d/t disruption of tubo-ovarian structure, or implants in ovaries)
    • Sx of intestinal obstruction
    • Sx of urethral obstruction
      • Urgency
      • Frequency
      • Can progress to post-renal failure
  • Physical exam
    • Visual inspection
      • Normal
    • Speculum exam
      • Normal
      • Occasional blue or powder-burn red lesions which bleed easily
    • Bimanual exam (variable)
      • Uterosacral nodularity and tenderness
      • Fixed retroverted uterus
      • Enlarged cystic adnexal mass
      • Fixed, firm posterior cul-de-sac
  • Gynaecologic differentials
    • Pelvic inflammatory disease (TOA, Sapingitis, Endometritis): Hx HOB and other infectious sx, Hx of untreated STDs
    • Hemorrhagic ovarian cyst
    • Ovarian torsion
    • Primary dysmenorrhea
    • Degenerating leiomyoma
    • Ectopic pregnancy
  • Investigations
    • Labs
      • CBC
      • Urine hCG
      • Urinalysis + culture
      • Vaginal/Cervical culture
    • Imaging
      • Transvaginal ultrasound
        • Uterine is not enlarged (generally, unlike adenomyosis)
        • Chocolate cysts
        • Nodules
      • CT, MRI
    • Diagnostic laparoscopy: definitive dx
  • Medical Treatment
    • NSAIDS (Ibruprofen, Naproxen): First-line Tx for primary dysmenorrhoea, pelvic pain prior to laparoscopy, or confirmed endometriosis w/mild sx
    • Combined oral contraceptives (COCs)
    • Progestins
      • DMPA (decreases BMD)
      • Norethindrone acetate (very effective with Leuprolide)
      • Levonorgestrel IUD (Mirena)
      • Ulipristal acetate(Ella)
      • Mifepristone (off-label)
      • Norethisterone
    • Androgens (Danazol, Gestrinone; have a significant adverse effect profile)
    • GnRH agonists (Leuprolide, Goserelin, Nafarelin)
    • Aromatase inhibitors (Anastrozole, Letrozole; second-line tx)
  • Surgical Treatment
    • Lesion ablation w/ adhesiolysis
    • Endometrioma resection
    • Presacral neurectomy
    • Hysterectomy w/ BSO: most definitive surgical tx. Considered in women who are done bearing children.
Transvaginal ultrasound showing uterosacral nodules
Transvaginal ultrasound showing uterosacral nodules
Transvaginal ultrasound showing an ovarian cyst
Transvaginal ultrasound showing an ovarian cyst
Diagnostic laparoscopy showing endometriosis
Diagnostic laparoscopy showing endometriosis
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Post Discussion

Your email address will not be published. Required fields are marked *